["{\n\"step_by_step_thinking\": \"None of the provided documents contain information about HER2 immunoreactivity or its relationship to urothelial carcinoma. Therefore, it is impossible to determine whether HER2 immunoreactivity provides prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy.\",\n\"answer_choice\": \"B\"\n}"]